ChemCon Passes its Fourth FDA Inspection - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ChemCon Passes its Fourth FDA Inspection



ChemCon, a Freiburg, Germany-based contract research company that offers custom synthesis of APIs and fine chemicals, has announced that it successfully passed an FDA inspection.

The March 2014 inspection for GMP compliance was the fourth in the 17-year history of the company. The inspection examined all quality assurance systems of the company relating to production, equipment,manufacturing facilities, materials, and quality controls. No form 483 was issued, the quality systems were considered acceptable, and the inspection was classified as no action indicated, the company reports.

Source: ChemCon

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here